Antibody data
- Antibody Data
- Antigen structure
- References [16]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
- Flow cytometry [5]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NB100-168 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NB100-168, RRID:AB_10002128
- Product name
- Mouse Monoclonal MGMT Antibody
- Antibody type
- Monoclonal
- Description
- Protein G purified.
- Reactivity
- Human, Mouse
- Host
- Mouse
- Isotype
- IgG
- Vial size
- 0.1 ml
- Concentration
- 1.0 mg/ml
- Storage
- Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Submitted references Effects of Some Growth Factors and Cytokines on the Expression of the Repair Enzyme MGMT and Protein MARP in Human Cells In Vitro : Effect of Some Growth Factors and Cytokines.
MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.
Temozolomide promotes genomic and phenotypic changes in glioblastoma cells.
IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation.
HSP90 regulates DNA repair via the interaction between XRCC1 and DNA polymerase β.
Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells.
Human O6 -methylguanine-DNA methyltransferase containing C145A does not prevent hepatocellular carcinoma in C3HeB/FeJ transgenic mice.
BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.
MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?
[Induction of repair enzyme O6-methylguanine-DNA methyltransferase gene expression under the influence of cytokine EMAP II in human cells in vitro].
N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma.
Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents.
O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma.
Human-yeast chimeric repair protein protects mammalian cells against alkylating agents: enhancement of MGMT protection.
Differential degradation rates of inactivated alkyltransferase in blood mononuclear cells and tumors of patients after treatment with O(6)-benzylguanine.
Kotsarenko K, Lylo V, Ruban T, Macewicz L, Lukash L
Biochemical genetics 2018 Oct;56(5):459-477
Biochemical genetics 2018 Oct;56(5):459-477
MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.
Altinoz MA, Elmaci I, Bolukbasi FH, Ekmekci CG, Yenmis G, Sari R, Sav A
Journal of chemotherapy (Florence, Italy) 2017 Aug;29(4):238-244
Journal of chemotherapy (Florence, Italy) 2017 Aug;29(4):238-244
Temozolomide promotes genomic and phenotypic changes in glioblastoma cells.
Stepanenko AA, Andreieva SV, Korets KV, Mykytenko DO, Baklaushev VP, Huleyuk NL, Kovalova OA, Kotsarenko KV, Chekhonin VP, Vassetzky YS, Avdieiev SS, Dmitrenko VV
Cancer cell international 2016;16:36
Cancer cell international 2016;16:36
IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation.
Oktay Y, Ülgen E, Can Ö, Akyerli CB, Yüksel Ş, Erdemgil Y, Durası IM, Henegariu OI, Nanni EP, Selevsek N, Grossmann J, Erson-Omay EZ, Bai H, Gupta M, Lee W, Turcan Ş, Özpınar A, Huse JT, Sav MA, Flanagan A, Günel M, Sezerman OU, Yakıcıer MC, Pamir MN, Özduman K
Scientific reports 2016 Jun 10;6:27569
Scientific reports 2016 Jun 10;6:27569
HSP90 regulates DNA repair via the interaction between XRCC1 and DNA polymerase β.
Fang Q, Inanc B, Schamus S, Wang XH, Wei L, Brown AR, Svilar D, Sugrue KF, Goellner EM, Zeng X, Yates NA, Lan L, Vens C, Sobol RW
Nature communications 2014 Nov 26;5:5513
Nature communications 2014 Nov 26;5:5513
Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells.
Kewitz S, Stiefel M, Kramm CM, Staege MS
Leukemia research 2014 Jan;38(1):138-43
Leukemia research 2014 Jan;38(1):138-43
Human O6 -methylguanine-DNA methyltransferase containing C145A does not prevent hepatocellular carcinoma in C3HeB/FeJ transgenic mice.
Herzig MC, Hildreth K, Huamani J, Perez M, Goins BA, McMahan CA, Reddick RL, Walter CA
Molecular carcinogenesis 2013 Apr;52(4):275-85
Molecular carcinogenesis 2013 Apr;52(4):275-85
BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.
Persano L, Pistollato F, Rampazzo E, Della Puppa A, Abbadi S, Frasson C, Volpin F, Indraccolo S, Scienza R, Basso G
Cell death & disease 2012 Oct 18;3:e412
Cell death & disease 2012 Oct 18;3:e412
MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?
Della Puppa A, Persano L, Masi G, Rampazzo E, Sinigaglia A, Pistollato F, Denaro L, Barzon L, Palù G, Basso G, Scienza R, d'Avella D
Journal of neuro-oncology 2012 Jan;106(1):33-41
Journal of neuro-oncology 2012 Jan;106(1):33-41
[Induction of repair enzyme O6-methylguanine-DNA methyltransferase gene expression under the influence of cytokine EMAP II in human cells in vitro].
Lylo VV, Matsevich LL, Kotsarenko EV, Babenko LA, Korneliuk AI, Sukhorada EM, Lukash LL
TSitologiia i genetika 2011 Nov-Dec;45(6):53-60
TSitologiia i genetika 2011 Nov-Dec;45(6):53-60
N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Tang JB, Svilar D, Trivedi RN, Wang XH, Goellner EM, Moore B, Hamilton RL, Banze LA, Brown AR, Sobol RW
Neuro-oncology 2011 May;13(5):471-86
Neuro-oncology 2011 May;13(5):471-86
Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma.
Pistollato F, Abbadi S, Rampazzo E, Persano L, Della Puppa A, Frasson C, Sarto E, Scienza R, D'avella D, Basso G
Stem cells (Dayton, Ohio) 2010 May;28(5):851-62
Stem cells (Dayton, Ohio) 2010 May;28(5):851-62
Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents.
Cai S, Xu Y, Cooper RJ, Ferkowicz MJ, Hartwell JR, Pollok KE, Kelley MR
Cancer research 2005 Apr 15;65(8):3319-27
Cancer research 2005 Apr 15;65(8):3319-27
O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma.
Zuo C, Ai L, Ratliff P, Suen JY, Hanna E, Brent TP, Fan CY
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2004 Jun;13(6):967-75
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2004 Jun;13(6):967-75
Human-yeast chimeric repair protein protects mammalian cells against alkylating agents: enhancement of MGMT protection.
Roth TJ, Xu Y, Luo M, Kelley MR
Cancer gene therapy 2003 Aug;10(8):603-10
Cancer gene therapy 2003 Aug;10(8):603-10
Differential degradation rates of inactivated alkyltransferase in blood mononuclear cells and tumors of patients after treatment with O(6)-benzylguanine.
Liu L, Spiro TP, Qin X, Majka S, Haaga J, Schupp J, Willson JK, Gerson SL
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Aug;7(8):2318-24
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Aug;7(8):2318-24
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Simple Western: MGMT Antibody (MT 23.2) [NB100-168] - Simple Western lane view shows a specific band for MGMT in 0.2 mg/ml of MCF-7 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: MGMT Antibody (MT 23.2) [NB100-168] - Detection of MGMT in MCF7 lysate using NB100-168 at 1:1000 dilution.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: MGMT Antibody (MT 23.2) [NB100-168] - IHC analysis of a formalin fixed paraffin-embedded (FFPE) human kidney using 1:2000 conc. of MGMT antibody (clone MT 23.2) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Nuclear staining of MGMT was observed. Staining was performed by Histowiz.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: MGMT Antibody (MT 23.2) [NB100-168] - Detection of MGMT in Human Jurkat Cell Line by Flow Cytometry. Human Jurkat cell line was stained with Mouse Anti- MGMT Monoclonal Antibody (Catalog # NB100-168, filled histogram), or Mouse IgG2B isotype control (Catalog # MAB0041, open histogram) followed by APC-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). To facilitate intracellular staining, cells were fixed with FlowX FoxP3 Fixation & Permeabilization Buffer Kit (Catalog # FC012).Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow (Intracellular): MGMT Antibody (MT 23.2) [NB100-168] - An intracellular stain was performed on Jurkat cells with MGMT Antibody (MT 23.2) antibody NB100-168 (blue) and a matched isotype control NBP2-27231 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow (Intracellular): MGMT Antibody (MT 23.2) [NB100-168] - An intracellular stain was performed on Raji cells with MGMT Antibody (MT 23.2) antibody NB100-168AF647 (blue) and a matched isotype control NBP2-27231AF647 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow (Intracellular): MGMT Antibody (MT 23.2) [NB100-168] - An intracellular stain was performed on Jurkat cells with MGMT Antibody (MT 23.2) antibody NB100-168AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: MGMT Antibody (MT 23.2) [NB100-168] - An intracellular stain was performed on HeLa cells with MGMT Antibody (MT 23.2) antibody NB100-168 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) PE-conjugated secondary antibody (F0102B, R&D Systems).